Kura Oncology Inc (KURA)
10.80
+0.74
(+7.36%)
USD |
NASDAQ |
Nov 22, 16:00
10.80
0.00 (0.00%)
After-Hours: 20:00
Kura Oncology Cash from Operations (Quarterly): -43.44M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -43.44M |
| June 30, 2024 | -42.53M |
| March 31, 2024 | -48.84M |
| December 31, 2023 | -34.31M |
| September 30, 2023 | -29.03M |
| June 30, 2023 | -25.62M |
| March 31, 2023 | -35.87M |
| December 31, 2022 | -26.53M |
| September 30, 2022 | -21.01M |
| June 30, 2022 | -30.34M |
| March 31, 2022 | -32.18M |
| December 31, 2021 | -23.37M |
| September 30, 2021 | -24.59M |
| June 30, 2021 | -28.07M |
| March 31, 2021 | -28.52M |
| December 31, 2020 | -18.31M |
| September 30, 2020 | -16.97M |
| June 30, 2020 | -14.73M |
| March 31, 2020 | -19.82M |
| December 31, 2019 | -13.93M |
| Date | Value |
|---|---|
| September 30, 2019 | -12.14M |
| June 30, 2019 | -14.43M |
| March 31, 2019 | -14.25M |
| December 31, 2018 | -10.21M |
| September 30, 2018 | -13.00M |
| June 30, 2018 | -12.59M |
| March 31, 2018 | -12.85M |
| December 31, 2017 | -7.474M |
| September 30, 2017 | -6.235M |
| June 30, 2017 | -6.11M |
| March 31, 2017 | -8.622M |
| December 31, 2016 | -6.738M |
| September 30, 2016 | -5.472M |
| June 30, 2016 | -5.825M |
| March 31, 2016 | -7.314M |
| December 31, 2015 | -5.605M |
| September 30, 2015 | -4.43M |
| June 30, 2015 | -3.767M |
| March 31, 2015 | -4.123M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-48.84M
Minimum
Mar 2024
-13.93M
Maximum
Dec 2019
-27.90M
Average
-27.30M
Median
Cash from Operations (Quarterly) Benchmarks
| Halozyme Therapeutics Inc | 115.38M |
| AIM ImmunoTech Inc | -3.11M |
| Perspective Therapeutics Inc | 3.366M |
| Protalix BioTherapeutics Inc | 4.105M |
| Armata Pharmaceuticals Inc | -8.863M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 45.54M |
| Cash from Financing (Quarterly) | 2.202M |
| Free Cash Flow | -169.24M |
| Free Cash Flow Per Share (Quarterly) | -0.4996 |
| Free Cash Flow Yield | -18.72% |